Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Giulia Masiero
Based on 4 articles published since 2009
(Why 4 articles?)

Between 2009 and 2019, Giulia Masiero wrote the following 4 articles about Coronary Artery Disease.
+ Citations + Abstracts
1 Guideline A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. 2018

Rossini, Roberta / Tarantini, Giuseppe / Musumeci, Giuseppe / Masiero, Giulia / Barbato, Emanuele / Calabrò, Paolo / Capodanno, Davide / Leonardi, Sergio / Lettino, Maddalena / Limbruno, Ugo / Menozzi, Alberto / Marchese, U O Alfredo / Saia, Francesco / Valgimigli, Marco / Ageno, Walter / Falanga, Anna / Corcione, Antonio / Locatelli, Alessandro / Montorsi, Marco / Piazza, Diego / Stella, Andrea / Bozzani, Antonio / Parolari, Alessandro / Carone, Roberto / Angiolillo, Dominick J / Anonymous911159 / Anonymous921159 / Anonymous931159 / Anonymous941159 / Anonymous951159 / Anonymous961159 / Anonymous971159 / Anonymous981159 / Anonymous991159 / Anonymous1001159 / Anonymous1011159 / Anonymous1021159 / Anonymous1031159 / Anonymous1041159 / Anonymous1051159 / Anonymous1061159 / Anonymous1071159 / Anonymous1081159 / Anonymous1091159 / Anonymous1101159 / Anonymous1111159 / Anonymous1121159 / Anonymous1131159. ·Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy. Electronic address: roberta.rossini2@gmail.com. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy. · Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy. · Division of Cardiology, Department of Cardio-Thoracic Sciences, Università degli Studi della Campania "Luigi Vanvitelli," Naples, Italy. · Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda Ospedaliero Universitaria "Policlinico-Vittorio Emanuele, Catania, Italy; Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. · Coronary Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. · Cardiovascular Department, Humanitas Research Hospital, Rozzano, Italy. · U.O.C. Cardiologia, Azienda USL Toscana Sudest, Grosseto, Italy. · Unità Operativa di Cardiologia, Azienda Ospedaliero-Universitaria di Parma, Italy. · U.O.C. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari, Italy. · Cardiology Unit, Cardio-Thoraco-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. · Swiss Cardiovascular Centre Bern, Bern University Hospital, Bern, Switzerland. · Degenza Breve Internistica e Centro Trombosi ed Emostasi, Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy. · Department of Immunohematology and Transfusion Medicine, Thrombosis and Hemostasis Center, ASST Papa Giovanni XXIII, Bergamo, Italy. · Department of Anaesthesia and Critical Care, AORN Dei Colli, Naples, Italy. · Dipartimento di Chirurgia Generale, Humanitas Research Hospital and University, Milano, Italy. · Policlinico Vittorio Emanuele di Catania, Catania, Italy. · Chirurgia Vascolare, Università di Bologna, Ospedale Sant'Orsola-Malpighi, Bologna, Italy. · UOC Chirurgia Vascolare, Dipartimento di Scienze Chirurgiche, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. · Dipartimento di Scienze Biomediche per la Salute, Policlinico San Donato IRCCS, University of Milano, Milan, Italy. · Azienda Ospedaliera Universitaria Città della salute e della scienza, Torino, Italy. · Division of Cardiology, University of Florida, College of Medicine-Jacksonville, Jacksonville, Florida. ·JACC Cardiovasc Interv · Pubmed #29519377.

ABSTRACT: Perioperative management of antithrombotic therapy in patients treated with coronary stents undergoing surgery remains poorly defined. Importantly, surgery represents a common reason for premature treatment discontinuation, which is associated with an increased risk in mortality and major adverse cardiac events. However, maintaining antithrombotic therapy to minimize the incidence of perioperative ischemic complications may increase the risk of bleeding complications. Although guidelines provide some recommendations with respect to the perioperative management of antithrombotic therapy, these have been largely developed according to the thrombotic risk of the patient and a definition of the hemorrhagic risk specific to each surgical procedure, key to defining the trade-off between ischemia and bleeding, is not provided. These observations underscore the need for a multidisciplinary collaboration among cardiologists, anesthesiologists, hematologists and surgeons to reach this goal. The present document is an update on practical recommendations for standardizing management of antithrombotic therapy management in patients treated with coronary stents (Surgery After Stenting 2) in various types of surgery according to the predicted individual risk of thrombotic complications against the anticipated risk of surgical bleeding complications. Cardiologists defined the thrombotic risk using a "combined ischemic risk" approach, while surgeons classified surgeries according to their inherent hemorrhagic risk. Finally, a multidisciplinary agreement on the most appropriate antithrombotic treatment regimen in the perioperative phase was reached for each surgical procedure.

2 Clinical Trial "Full-plastic jacket" with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413). 2018

Tarantini, Giuseppe / Masiero, Giulia / Fovino, Luca Nai / Mojoli, Marco / Varricchio, Attilio / Loi, Bruno / Gistri, Roberto / Misuraca, Leonardo / Gabrielli, Gabriele / Cortese, Bernardo / Pisano, Francesco / Moretti, Luciano / Tumminello, Gabriele / Olivari, Zoran / Mazzarotto, Pietro / Colombo, Alessandro / Calabrò, Paolo / Nicolino, Annamaria / Tellaroli, Paola / Corrado, Donatella / Durante, Alessandro / Steffenino, Giuseppe / Anonymous2021030. ·Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. Electronic address: giuseppe.tarantini.1@unipd.it. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Interventional Cardiology, A.O. Monaldi, Naples, Italy. · Cardiology Division, A.O. Brotzu, Cagliari, Italy. · Interventional Cardiology, S. Andrea Hospital, La Spezia, Italy. · U.O. Cardiologia-Emodinamica, Ospedale della Misericordia, Grosseto, Italy. · Interventional Cardiology Unit, Azienda Ospedali Riuniti, Ancona, Italy. · Interventional Cardiology, A.O. Fatebenefratelli, Milan, Italy. · Interventional Cardiology, Parini Regional Hospital, Aosta, Italy. · Cardiology Division, Mazzoni Hospital, Ascoli Piceno, Italy. · Cardinal Massaia Hospital, Asti, Italy. · Cardiology Division, Ca' Foncello Hospital, Treviso, Italy. · Interventional Cardiology, Ospedale Maggiore, Lodi, Italy. · Interventional Cardiology Unit, Luigi Sacco Hospital, Milano, Italy. · Division of Cardiology, Department of Cardio-Thoracic Sciences, Second University of Naples, Naples, Italy. · Interventional Cardiology Unit, Santa Corona General Ospital, Pietra Ligure, Italy. · Biostatistics, Epidemiology and Public Health Unit of Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · "Mario Negri" Research Institute, Milano, Italy. · Cardiology Division, Valduce Hospital, Como, Italy. · USD Emodinamica, A.S.O. S.Croce e Carle, Cuneo, Italy. ·Int J Cardiol · Pubmed #29887475.

ABSTRACT: OBJECTIVES: The objective of this study was to investigate mid-term clinical outcomes of patients treated with 'full-plastic jacket' (FPJ) everolimus-eluting Absorb bioresorbable vascular scaffold (BRS) implantation. BACKGROUND: FPJ with BRS may represent an interesting option for patient with diffuse coronary artery disease (CAD), but data on the clinical impact of FPJ using the Absorb BRS are scant. METHODS: FPJ was defined as the implantation of >56 mm of overlapping BRS in at least one vessel. We compared outcomes of patients receiving Absorb FPJ vs. non-FPJ within the multicenter prospective RAI Registry. RESULTS: Out of 1505 consecutive patients enrolled in the RAI registry, 1384 were eligible for this analysis. Of these, 143 (10.3%) were treated with BRS FPJ. At a median follow-up of 649 days, no differences were observed between FPJ and non-FPJ groups in terms of the device-oriented composite endpoint (DoCE) (5.6% vs. 4.4%, p = 0.675) or the patient-related composite endpoint (PoCE) (20.9% vs. 15.9%, p = 0.149). Patients receiving FPJ had higher rates of target vessel repeat revascularization (TVR) (11.2% vs. 6.3%, p = 0.042). In the FPJ group, there was no cardiac death and only one (very late) stent thrombosis (ST) (0.7%). CONCLUSIONS: Mid-term outcomes of a FPJ PCI strategy in the setting of diffuse CAD did not show a significant increase in composite device- and patient-related events, with rates of cardiac death and ST comparable to non-FPJ Absorb BRS implantation. However, these findings are hypothesis generating and requiring further validation.

3 Article Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. 2018

Tarantini, Giuseppe / Masiero, Giulia / Barioli, Alberto / Paradies, Valeria / Vlachojannis, Georgios / Tellaroli, Paola / Cortese, Bernardo / di Palma, Gaetano / Varricchio, Attilio / Ielasi, Alfonso / Loi, Bruno / Steffenino, Giuseppe / Ueshima, Daisuke / Mojoli, Marco / Smits, Pieter. ·Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Maastad Ziekenhuis, Rotterdam, Netherlands. · Biostatistics, Epidemiology and Public Health Unit of Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Unità Operativa di Cardiologia, ASST Fatebenefratelli-Sacco, P.O. Fatebenefratelli, Italy. · Cardiology Division, Santa Maria della Pietà Hospital, Nola, Naples, Italy. · Cardiology Division, A.O. Bolognini, Seriate, Bergamo, Italy. · Cardiology Division, A.O. Brotzu, Cagliari, Italy. · USD Emodinamica, A.S.O. S.Croce e Carle, Cuneo, Italy. ·Catheter Cardiovasc Interv · Pubmed #29513403.

ABSTRACT: BACKGROUND: Patients with small vessel disease (SVD) are at higher risk of adverse events after PCI compared to non-SVD patients. In this subset, the use of bioresorbable vascular scaffolds (BVS) has raised particular concern. OBJECTIVE: We aimed to compare outcomes of Absorb BVS versus a 2nd-generation metallic everolimus-eluting stents (EES) in the SVD setting, by pooling patients from three large, prospective studies. METHODS: Patients with SVD (reference vessel diameter ≤2.75 mm by QCA) and treated with Absorb BVS were identified in the Italian RAI and the MAASSTAD-Absorb registries. EES controls were identified in the COMPARE II Trial. We performed a propensity-score matching using several clinical and angiographic variables. Implantation technique was not object of matching, being device-specific. RESULTS: Out of 4635 enrolled subjects, 1147 belonged to the SVD population. After matching, we obtained 337 pairs of patients. High clinical and angiographic complexity was found in both groups. Predilation and postdilation rates were significantly higher in BVS patients. No differences were found in terms of the device-oriented composite end-point at 1-year (HR = 1.08, 95%CI 0.5-2.3, P = .8) and 2-years (HR = 1.28, 95% CI: 0.68-2.43, P = .5). Notwithstanding, higher incidence of definite/probable stent thrombosis was observed in the BVS group at 1 year (HR 4.7, 95%CI 0.8-31.4, P = .08) and 2-years (HR = 8.34 95%CI 1.1-60.2, P = .04). CONCLUSION: In this propensity-matched analysis pooling SVD patients of three large prospective studies, incidence of composite device-related events was comparable between BVS and EES up to 2 years follow-up. However, higher rates of stent thrombosis were found in the BVS group.

4 Article [Bioresorbable vascular scaffolds: from science to clinical parctice]. 2017

Masiero, Giulia / Tarantini, Giuseppe. ·Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari, Università degli Studi, Padova. ·G Ital Cardiol (Rome) · Pubmed #28398397.

ABSTRACT: -- No abstract --